MTRAC guidance on DPP-4 inhibitors (‘Gliptins’) for the treatment of type 2 diabetes -

MTRAC guidance on DPP-4 inhibitors (‘Gliptins’) for the treatment of type 2 diabetes
Information type: Evidence summaries
Source: Midlands Therapeutics Review and Advisory Committee
Specialities: Diabetes
Summary
No significant differences were reported between gliptins with respect to blood glucose-lowering efficacy vs. other oral diabetic treatments in systematic review evidence, or in 1 RCT head-to-head comparison of sitagliptin and saxagliptin.
UKMi comment
The full text of this guidance sheet is restricted to subscriber CCGs for a period of 3 months from first publication; it will then be made freely and publicly available.
Related links: